Literature DB >> 24438420

Topical timolol for a chronic ulcer--a case with its own control.

Melissa N Manahan1, Peter Peters2, Salvatore Scuderi2, Devita Surjana2, Graeme L Beardmore2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24438420     DOI： 10.5694/mja13.10823

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  4 in total

Review 1.  Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events.

Authors:  Daniel J Yoon; Ramanjot Kaur; Anthony Gallegos; Kaitlyn West; Hsinya Yang; Saul Schaefer; Catherine Tchanque-Fossuo; Sara E Dahle; R Rivkah Isseroff
Journal:  Am J Clin Dermatol       Date:  2020-11-25       Impact factor: 7.403

2.  Efficacy and Safety of 0.25% Timolol Gel in Healing Split-Thickness Skin Graft Site.

Authors:  Amirhossein Ghanbarzamani; Ebrahim Salehifar; Abdolreza Jafarirad; Mohammad Hossein Hesamirostami; Ali Bagherzadehsaba; Majid Saeedi; Monireh Ghazaeian; Ghasemali Khorasani; Mahmood Moosazadeh
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

3.  β2-adrenoceptor activation modulates skin wound healing processes to reduce scarring.

Authors:  Gabrielle S Le Provost; Christine E Pullar
Journal:  J Invest Dermatol       Date:  2014-07-22       Impact factor: 8.551

4.  Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study.

Authors:  Ramanjot Kaur; Catherine Tchanque-Fossuo; Kaitlyn West; Yasmin Hadian; Anthony Gallegos; Daniel Yoon; Ligia Ismailyan; Saul Schaefer; Sara E Dahle; R Rivkah Isseroff
Journal:  Trials       Date:  2020-06-08       Impact factor: 2.279
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.